Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSGSK5182 is an inverse agonist of estrogen-related receptor γ (ERRγ; IC50 = 77 nM in a reporter assay) and a derivative of (Z)-4-hydroxy tamoxifen (Item No. 14854).1 It selectively binds to ERRγ over ERα, ERRα, and ERRβ (IC50s = 0.11, 2, >10, and >10 µM, respectively). GSK5182 enhances radioiodine uptake and membrane localization of the sodium/iodide symporter (NIS) in BHT-101 and CAL-62 anaplastic thyroid cancer cells.2 It inhibits osteoclastogenesis induced by RANKL and macrophage colony-stimulating factor (M-CSF) in primary mouse bone marrow-derived macrophages (BMDMs) and induces apoptosis in osteoclasts when used at a concentration of 10 µM.3 GSK5182 (10 µM) inhibits fibrinogen secretion induced by the cannabinoid 1 (CB1) receptor agonist ACEA (arachidonoyl 2'-chloroethylamide; Item No. 91054) in AML12 hepatocytes.4 In vivo, GSK5182 (40 mg/kg) decreases blood glucose levels in a pyruvate tolerance test in a mouse model of high-fat diet-induced obesity.5
WARNING This product is not for human or veterinary use.
1. Discovery of potent, selective, and orally bioavailable estrogen-
2. Inverse agonist of estrogen-
3. The estrogen-
4. Inverse agonist of ERRγ reduces cannabinoid receptor type 1-
5. Inverse agonist of nuclear receptor ERRγ mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes 62(9), 3093-3102 (2013).